“…It is worthy of note that HIV protease inhibitors such as ritonavir, saquinavir, indinavir and lopinavir strongly reduce MMP-9 expression and/or activity in normal or cancer cells and in treated patients [ 20 , 169 , 170 , 171 , 172 , 173 , 174 ]. This is because HIV protease inhibitors repress the MAPK/ERK and/or PI3K/AKT signaling pathways, thereby functionally impairing transcription factors targeting the mmp-9 gene, including NF-kB, Specificity protein-1 or the Fra-1 element of the Activator Protein-1 transcriptional complex [ 164 , 169 , 175 , 176 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 , 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 , 195 , 196 ]. It should be noted that the AKT activation process starts when PI3K promotes the production of phosphatidylinositol-3,4,5-trisphosphate (PIP3); this is followed by AKT recruitment to the cell membrane and AKT phosphorylation on Thr308 and Ser473 by the phosphoinosotide-dependent kinase-1 and the mammalian target of rapamycin, respectively [ 191 ].…”